NCT07311798Not yet recruiting
Impact of Vascular Resection on Survival and Postoperative Outcomes in Patients With Hilar Cholangiocarcinoma: A Retrospective Study
Source: ClinicalTrials.gov · Last updated 31 Dec 2025
Brief summary (registry, in English)
Hilar cholangiocarcinoma is a highly aggressive malignancy, and surgical resection remains the only potentially curative treatment. Due to the frequent involvement of major vascular structures, vascular resection is increasingly performed to achieve negative surgical margins; however, its impact on survival and postoperative outcomes remains controversial. This retrospective study aims to evaluate the association between vascular resection and clinical outcomes, including survival and postoperative outcomes, in patients with hilar cholangiocarcinoma undergoing curative-intent surgery.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 16 Dec 2025
- Start date
- Dec 2025
- Primary completion date
- Jan 2026
- Lead sponsor
- Yongjun Chen
- NCT number
- NCT07311798
What you commit to
- Study type: Observational
- Planned participants: 300
- From Dec 2025 to the primary completion date, Jan 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with distant metastasis or who underwent only palliative or exploratory surgery.
Other illness
- Patients diagnosed preoperatively or intraoperatively with other types of biliary malignancies not located at the hilar region.
Other
- Patients with incomplete medical records or missing key clinical or follow-up data.
Who the study is looking for
- Patients who underwent surgical treatment at the Department of Hepatobiliary and Pancreatic Surgery of our hospital between January 2010 and December 2024, including those with or without concomitant vascular resection.
- Pathologically confirmed diagnosis of hilar cholangiocarcinoma after surgery.
- Complete clinical and follow-up data available for outcome analysis.
Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.